JOHNSON JOHNSON THAILAND PROVIDES HOLISTIC DIABETES CARE SOLUTIONS WITH NEW IN-STORE PROGRAM AT FASCINO TO MARK WORLD DIABETES DAY

Food and Healthcare Press Releases Wednesday December 6, 2017 13:55
Bangkok--6 Dec--Johnson & Johnson

Johnson & Johnson (Thailand) Limited marked World Diabetes Day this month by launching a new in-store holistic diabetes care program at FASCINO, one of the leading pharmacy chains operating in Thailand. The program aims to provide access to diabetes management information and solutions at a specialized location within each of the 43 outlets of the FASCINO network across the country.

In Thailand, around 6.5 Million people have Diabetes and the prevalence is likely to increase by 10% every year. The initiative covers all aspects of self-care through a unique in-store set-up including oral health, skin care, and foot care that play an important role in daily management of the condition in addition to blood sugar monitoring and taking medicines consistently.

Mr. Neeraj Goyal, Marketing Director of Johnson & Johnson (Thailand) Limited said "Johnson & Johnson is committed towards health and wellness of consumer & patient in Thailand and it is continuously addressing the well-being of people in Thailand. Diabetes was identified as one of the disease areas where more support could be provided at a retail level to consumers and patients."

"Johnson & Johnson has a strong legacy and expertise in diabetes care and FASCINO is one of the most reputable pharmacies in Thailand with a widespread network. Through this initiative we shall be reaching out to a large number of people across the country to educate them on the disease state and also provide solutions to enable holistic management of their health and wellness associated with diabetes outside of medical and hospital care. These include our consumer range of products from Aveeno for skincare to Listerine for oral hygiene as well as blood glucose monitoring meters and solutions for pain management, provided through a unique in-store display for easy access and certain long term measures like smoking cessation."

Pharmacist Chaisen Pisanwaler, Managing Director, Profascino Co., Ltd said "the community pharmacy can play a key role in helping to improve the quality of life of those impacted by diabetes. We are proud to have introduced this one-of-a kind initiative at a retail level that addresses an important healthcare need for Thai people through a well-selected range of products and their related educational materials for holistic diabetes care.The initiative has been well-received by consumers across FASCINO stores and we are looking forward to working together with Johnson & Johnson on other such programs in the near future".

About Johnson & Johnson

Caring for the world one person at a time inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 132,500 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

*From the statistic, the number and rate of people affected diabetes (E10-E14) per 100,000 people (including all diagnostics) in year 2007 - 2014

Latest Press Release

Medical Device Manufacturer Advant Medical Celebrates Its 25th Anniversary

Advant is a successful medical device manufacturer with corporate offices located in Galway, Ireland. For a quarter of a century, Advant has seen significant growth and development expanding into two locations in Ireland, Mexico and Costa Rica. With over...

Michel Orsinger Assumes Role as Chairman of Limacorporate#s Advisory Board

LimaCorporate is pleased to announce that Michel Orsinger, Board Member of LimaCorporate's Advisory Board, will assume the role of Chairman of the Board. Michel joined the Advisory Board mid-2017 following a long and successful global career in...

Merck and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxorubicin (PLD), a type of chemotherapy, compared with PLD did not meet the...

APEC#s Rare Disease Action Plan Sets Precedent to Integrate Rare Disease Care by 2025

- Asia-Pacific Economic Cooperation (APEC) Life Sciences Innovation Forum (LSIF) Rare Disease Network comprises Rare Disease International, Queensland University of Technology and Shire (representing as industry co-chair). - Aims to define, diagnose and...

Grunenthal Acquires Averitas Pharma and Establishes Commercial Footprint in the US

Grunenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be commercialising the pain patch Qutenza(R) (8 % capsaicin) for...

Related Topics